Association between hypomagnesemia and mortality among dialysis patients: a systematic review and meta-analysis
Authors:
Open Access
Abstract
Background: Malnutrition-inflammation-atherosclerosis (MIA) syndrome is caused by the inflammatory cytokines in end stage renal disease (ESRD) patients, and MIA complex-related factors may be associated with hypomagnesemia and mortality. However, the association between serum magnesium level and mortality for dialysis patients is still not clear. Additionally, no meta-analysis has investigated the impact of serum magnesium on peritoneal dialysis and hemodialysis, separately. Methods: We searched published studies in PubMed, Embase, Cochrane, Collaboration Central Register of Controlled Clinical Trials, and Cochrane Systematic Reviews through April 2022. Studies associated with serum magnesium and all-cause mortality or cardiovascular (CV) mortality in ESRD on kidney replacement therapy (KRT) patients were included. A hazard ratio (HR) with 95% confidence intervals (CI) was used to report the outcomes. Results: Twenty-one studies involving 55,232 patients were included. Overall, there was a significant association between hypomagnesemia and all-cause mortality for dialysis patients (HR: 1.67, 95% CI [1.412–2.00], p < 0.001; certainty of evidence: moderate) using a mixed unadjusted and adjusted HR for analysis. There was also a significantly increased risk of CV mortality for individuals with hypomagnesemia compared with the non-hypomagnesemia group (HR 1.56, 95% CI [1.08–2.25], p < 0.001; certainty of evidence: moderate). In addition, a subgroup analysis demonstrated that hypomagnesemia was associated with a high risk of both all-cause mortality and CV mortality (all-cause mortality, HR:1.80, 95% CI [1.48–2.19]; CV mortality, HR:1.84, 95% CI [1.10–3.07]) in hemodialysis (HD) patients, but not in participants receiving peritoneal dialysis (PD; all-cause mortality, HR:1.26, 95% CI [0.84–1.91]; CV mortality, HR:0.66, 95% CI [0.22–2.00]). The systematic review protocol was prespecified and registered in PROSPERO [CRD42021256187]. Conclusions: Hypomagnesemia may be a significant risk factor for all-cause mortality and CV mortality in KRT patients, especially in those receiving hemodialysis. However, because of the limited certainty of evidence, more studies are required to investigate this association.Keywords
Funding Information
- Chi-Mei Medical Center (CMFHR10973)
This publication has 51 references indexed in Scilit:
- The Role of Serum Magnesium and Calcium on the Association between Adiponectin Levels and All-Cause Mortality in End-Stage Renal Disease PatientsPLOS ONE, 2012
- Relationship between Magnesium and Clinical Biomarkers on Inhibition of Vascular CalcificationAmerican Journal of Nephrology, 2011
- The Cochrane Collaboration's tool for assessing risk of bias in randomised trialsBMJ, 2011
- Magnesium, the Metabolic Syndrome, Insulin Resistance, and Type 2 Diabetes MellitusCritical Reviews in Food Science and Nutrition, 2008
- Renovascular hypertension by two-kidney one-clip enhances endothelial progenitor cell mobilization in a p47phox-dependent mannerJournal Of Hypertension, 2008
- Cardiovascular risk factors in chronic kidney diseaseKidney International, 2005
- Low magnesium promotes endothelial cell dysfunction: implications for atherosclerosis, inflammation and thrombosisBiochimica et Biophysica Acta (BBA) - Molecular Basis of Disease, 2004
- Possible roles of magnesium on the immune systemEuropean Journal of Clinical Nutrition, 2003
- Role of magnesium in insulin action, diabetes and cardio-metabolic syndrome XMolecular Aspects of Medicine, 2003
- Impaired tyrosine-kinase activity of muscle insulin receptors from hypomagnesaemic ratsDiabetologia, 1995